SU839547A1 - Method of obtaining leukocytic interferon - Google Patents
Method of obtaining leukocytic interferon Download PDFInfo
- Publication number
- SU839547A1 SU839547A1 SU792750539A SU2750539A SU839547A1 SU 839547 A1 SU839547 A1 SU 839547A1 SU 792750539 A SU792750539 A SU 792750539A SU 2750539 A SU2750539 A SU 2750539A SU 839547 A1 SU839547 A1 SU 839547A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- interferon
- obtaining
- expand
- virus
- incubated
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
(54) СПОСОБ ПОЛУЧЕНИЯ ЛЕЙКОЦИТАРНОГО ИНТЕРФЕРОНА(54) METHOD FOR OBTAINING LEUKOCITARNY INTERFERON
с т евиной лейкоцитарный интерферон в количестве 100 ед. на 1 мл суспензии. Смесь инкубируют 2ч при затем центрифугируют дл отделени клеток от среды, клеки вновь суспензируют в свежей среде 199 с 10%-ной АМЖ, после чего в суспензию внос т вирус-ин .:дуктор. Титр ВБН определ ют предварительно в культуре куриных фибробластов .with t evinous leukocyte interferon in the amount of 100 units. on 1 ml of suspension. The mixture is incubated for 2 hours, then centrifuged to separate the cells from the medium, the glue is re-suspended in fresh medium 199 with 10% AMJ, after which the virus-in. Suspension is added to the suspension. VBN titer is pre-determined in a chicken fibroblast culture.
на I И этапе Определ ют антивирусную активность. Двухкратные разведени интерфероносодержаадей жидкости внос т в пробирки с трехдневной культурой диплоидных.клеток человека и через 1&-20 ч инкубации при в те же пробирки внос т вирус-индикатор (вирус везикул рного стоматика ВВС, штамм Индиана ) в дозе 100 unflggHa пробирку. Через 48 ч инкубировани при ,in stage I and stage Antiviral activity is determined. Twofold dilutions of the interferon-containing liquid are introduced into test tubes with a three-day culture of human diploid cells and after 1 & 20 h of incubation, an indicator virus (the air force vesicular dental virus, Indiana strain) is introduced in the same test tube at a dose of 100 unflggHa tube. After 48 h of incubation at
при условии наступлени полной дегенерации клеток в контрольных пробирках с культурой ткани, не обработанной интерференом, но инфицированной вирусом, определ ют последнее разведение интерферона, защитившее клетки от вирусной деструкции . Это разведение принимают за титр интерферона и выражают его в единицах ме хдународного стандарта Б 69/19.subject to the onset of complete cell degeneration in control tubes with a tissue culture that was not treated with an interference, but infected with a virus, the last dilution of interferon was determined, which protected the cells from viral destruction. This dilution is taken as an interferon titer and expressed in units of international standard B 69/19.
Средний титр свиного лейкоцитарного интерферона в культуре диплоидных клеток человека 400М.ед/ в том случае, если интерферон получают без применени прайминг-метода , а при использовании его 10000 М.ед/мл. The average titer of porcine leukocyte interferon in human diploid cell culture is 400M. Units / if interferon is obtained without the priming method, and when using it is 10,000 M. units / ml.
В таблице представлена сравнителна , характеристика свиного и человеческого лейкоцитарного интерфероНОВ .The table shows the comparative characteristics of swine and human leukocyte interferons.
1333+4201333 + 420
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU792750539A SU839547A1 (en) | 1979-04-06 | 1979-04-06 | Method of obtaining leukocytic interferon |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU792750539A SU839547A1 (en) | 1979-04-06 | 1979-04-06 | Method of obtaining leukocytic interferon |
Publications (1)
Publication Number | Publication Date |
---|---|
SU839547A1 true SU839547A1 (en) | 1981-06-23 |
Family
ID=20821146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SU792750539A SU839547A1 (en) | 1979-04-06 | 1979-04-06 | Method of obtaining leukocytic interferon |
Country Status (1)
Country | Link |
---|---|
SU (1) | SU839547A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1983001899A1 (en) * | 1981-12-01 | 1983-06-09 | BÉLADI, Ilona | Process for the production of human gamma-interferon |
-
1979
- 1979-04-06 SU SU792750539A patent/SU839547A1/en active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1983001899A1 (en) * | 1981-12-01 | 1983-06-09 | BÉLADI, Ilona | Process for the production of human gamma-interferon |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4376821A (en) | Production of human IFN-gamma (immune) interferon | |
EP0253887B1 (en) | Low dosage of interferon to enhance vaccine efficiency | |
Valle et al. | Characteristics of immune interferon produced by human lymphocyte cultures compared to other human interferons | |
Levin et al. | Evaluation of the human interferon system in viral disease. | |
CN1098103C (en) | Methods and compositions for the treatment of diseases with interferon while reducing side effects | |
Kobayashi et al. | Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. | |
Rosenberg et al. | In vitro stimulation of sensitized lymphocytes by herpes simplex virus and vaccinia virus | |
US4376822A (en) | Production of human IFN- γ (immune) interferon | |
Vilček et al. | Superinduction of interferon with metabolic inhibitors: possible mechanisms and practical applications | |
OLESZAK et al. | Platelet-derived growth factor (PDGF) inhibits antiviral and anticellular action of interferon in synchronized mouse or human cells | |
Lehmann et al. | Infection of macrophages by influenza A virus: characteristics of tumour necrosis factor-α (TNFα) gene expression | |
US4614651A (en) | Interferon epsilon | |
EP0017570A1 (en) | Process for the preparation of interferon and culture medium composition used in it | |
JPS6154040B2 (en) | ||
Chen et al. | Synergistic anti-herpes effect of TNF-α and IFN-γ in human corneal epithelial cells compared with that in corneal fibroblasts | |
Einhorn et al. | Production and characterization of interferon from endothelial cells | |
SU839547A1 (en) | Method of obtaining leukocytic interferon | |
CN1134537C (en) | Separation, extracorporeal culture, preparation and application of human primitive mesenchymal stem cell population | |
Stewart et al. | Relative antiviral resistance induced in homologous and heterologous cells by cross-reacting interferons | |
EP0048283B1 (en) | Virus-inhibiting substance and process for preparing the same | |
NO173144B (en) | PROCEDURE FOR THE PREPARATION OF INTERFERON GAMES | |
FI941920A0 (en) | Method and composition for determining the immunological activity of bioactive substances | |
JP2001000179A (en) | Inactivation of virus | |
Hammar et al. | Induction of tubuloreticular structures in cultured human endothelial cells by recombinant interferon alfa and beta | |
Ohmann et al. | A neutrophil-derived antiviral protein: induction requirements and biological properties |